These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11001233)

  • 1. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.
    Raskin S; Durst R; Katz G; Zislin J
    J Clin Psychopharmacol; 2000 Oct; 20(5):500-3. PubMed ID: 11001233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
    Kotler M; Strous RD; Reznik I; Shwartz S; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2004 Jan; 19(1):23-6. PubMed ID: 15101566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
    Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
    Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
    Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
    Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe akathisia during olanzapine treatment of acute schizophrenia.
    Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C
    Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.
    Lerner V; Chudakova B; Kravets S; Polyakova I
    Clin Neuropharmacol; 2000; 23(5):284-6. PubMed ID: 11154098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of olanzapine: an overview of pivotal clinical trials.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
    Tollefson GD; Birkett MA; Kiesler GM; Wood AJ;
    Biol Psychiatry; 2001 Jan; 49(1):52-63. PubMed ID: 11163780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
    Swartz JR; Ananth J; Smith MW; Burgoyne KS; Gadasally R; Arai Y
    J Clin Psychiatry; 1999 Feb; 60(2):119-21. PubMed ID: 10084639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine.
    Hale AS
    Br J Hosp Med; 1997 Nov 5-18; 58(9):442-5. PubMed ID: 9619205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
    Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
    Molina JD; Toledo-Romero F; López-Rodríguez E; Amorin-Díaz M; Lerma-Carrillo I; López-Muñoz F
    Pharmacopsychiatry; 2011 Jun; 44(4):142-7. PubMed ID: 21710404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.